Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
590 Views
2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
511 Views
2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
656 Views
Alphamab Oncology: Trading Debut, Valuation Scenario Analysis
Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
489 Views
Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal
Alphamab, the leading bispecific antibodies player in China, raised USD 220 million at HKD 10.2 per share. In this insight, we will cover the...
487 Views